Replies to post #160 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Maybe they were all too busy focusing on starting a new company

Very excited to announce a new deal this morning! We are launching a newco, Orbital, to develop next-gen RNA therapies.

Orbital combines Beam technology/team + add'l RNA technologies + IP from Stanford + leading RNA founders + initial investment from ARCH a16z & Newpath.

— John Evans (@john_evans3) September 7, 2022

So far, cashing checks is the only thing they are good at!